Q-omics provides the consensus-scored FAM229B profile across patient tissues and cancer cell-line models. FAM229B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, FAM229B is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, FAM229B RNA expression shows 19,340 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, KICH, and GBM as cancer lineages where FAM229B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM229B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM229B survival associations across molecular data types. FAM229B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM229B RNA expression–survival associations across cancer types. High FAM229B expression shows unfavorable associations in STAD, BLCA and LUSC, but favorable associations in ESCA, LGG and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify STAD as the clearest survival context for FAM229B RNA expression.
This table summarizes FAM229B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FAM229B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM229B shows lower tumor expression in KICH, THCA, BLCA, LUAD, KIRC and LIHC. The KICH box plot shows higher FAM229B RNA expression in normal versus tumor tissue (log2 FC = −2.857, t-test p < 0.001).
This table shows molecular features associated with FAM229B in patient tissues and cancer cell lines. In patient samples, FAM229B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM229B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
